0
Obstructive Lung Diseases |

Real-Life Efficacy of Indacaterol and Other LABAs in COPD Patients in Israel FREE TO VIEW

Gabriel Izbicki, MD; David Shitrit, MD; Meir Raz, MD; Zeev Vilayi-Weiler, MD; Gershon Fink, MD; Yehuda Schwarz, MD; Sari Lubin, BA; Lital Daniel, MD; Tamar Rachmilewitz, MD; Mordechai Kramer, MD
Author and Funding Information

Novartis, Petach Tikva, Israel


Chest. 2014;145(3_MeetingAbstracts):431B. doi:10.1378/chest.1829807
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD Case Report Posters

SESSION TYPE: Case Report Poster

PRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PM

PURPOSE: Indacaterol (IND) is a once daily long acting beta 2 agonist (LABA). This study evaluated how IND can be introduced into real life treatment regimens for COPD in Israel.

METHODS: A 12 week multicenter, randomized, open label study in patients (Pts) with moderate to severe COPD, aged 40 years and older, whose current treatment regimen included a LABA. Pts were randomized to either change current LABA to IND, or to remain on their previous treatment. In both arms pts who were treated with inhaled corticosteroids (ICS) were allowed to continue ICS. The primary objective was change in health-related quality of life (HRQoL) measured by COPD Clinical Questionnaire (CCQ) score change from baseline to week 121.

RESULTS: 90 pts were randomized (60 to IND and 30 to control), mean age 65.2±9.9 yrs. At 12 weeks the IND arm demonstrated an improvement in HRQoL reflected by a decrease from baseline in mean±SEM CCQ score of 0.2±0.8.HRQoL deteriorated from baseline in the control group , with an increase in mean CCQ of 0.2±0.9.The 0.4 delta between the groups in CCQ score showed borderline statistical significance (Ptrend= 0.0595).This difference meets the CCQ score minimally important difference (0.4). Use of IND was not associated with any significant safety concerns.

CONCLUSIONS: Administration of once daily IND 150 mcg to COPD pts previously treated with other LABAs led to an improvement in pts’ QoL. The borderline statistical significance is probably due to the small number (90) of pts included in this study.

CLINICAL IMPLICATIONS: This study was designed to evaluate how IND can be introduced into real life treatment regimens for COPD, by effectively and safely replacing other LABA.

DISCLOSURE: Gabriel Izbicki: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium David Shitrit: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium Meir Raz: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium Zeev Vilayi-Weiler: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium Gershon Fink: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium Yehuda Schwarz: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium Sari Lubin: Employee: Salary Lital Daniel: Employee: Salary Tamar Rachmilewitz: Employee: Salary Mordechai Kramer: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543